Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF| NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $5.35 | Change: $0.00 | %Change: 0.00%
Volume: 10,613 | Day High/Low: 5.40/5.32 | 52 Week High/Low: 10.36/2.57
View modes: 
0 stars


I'll take  T D advise and  wait  for $ 4.00 .  rate and reply
0 stars


Good point. TNuvo will need to reference P2 sales in Q2, and that cant happen until Horizon reports on Aug 4....  rate and reply
0 stars

RE:Forward Glancing

Well put Rock. I agree that maintaing current P2 sales levels in the US  through the summer sets up for another increase through the fall and winter. The pace of sales also suggests that the more
0 stars


Its unlikely that Nuvo will announce its Q2 before Horizon. Aug 4 is Horizon's release date.  rate and reply
3.5 stars

Forward Glancing

There are several factors driving sales of topical Nsaids in the US. Interannually, Obamacare has expanded the scrioted patient population. Secondly, there is a substantial shift from oral Nsaids more
2.5 stars

RE:2j you are both wrong and offensive

Indeed not. You voted in two former auto execs with no background in biotech. Nuvo was bankrupt at that time. Funds had to be raised and new execs had to learn the ropes. The original deal more
2.5 stars

RE:2j you are both wrong and offensive

you as C99 all you do is cry and pollute the board... Bio  rate and reply
4.5 stars

2j you are both wrong and offensive

Longs such as 99 did not vote in Mutt and Jeff . They voted for a platform that has not been delivered and promised personal qualities that have been noticeably absent. We will continue to more
3 stars

RE:A little more than 7 years ago...

Hindsight is wonderful. Everyone bats100%. You folks voted current management in. Nuvo now has very  strong fundanentals and a very exciting future. Recent shareholders are the beneficiaries. more
0 stars


Its not obvious from last year's Q2 numbers why Nuvo would be burning through much cash in Q2 of 2015.Total revenues have at least doubled from 2014 and cash expenditures may only be a million or more
5 stars


Looks like its settling in around 8000 btls for July. Should pick up after mid August when holidays taper off. $75 million looks possible for Q3.  rate and reply
0 stars

Numbers are out

Shy under 8000  rate and reply
3.5 stars

A little more than 7 years ago...

Contrast what Nuvo lost out on being late to the party. Two deals later and we are still not up to what was given out for the initial Voltaren 5-year agreement and Nuvo had to sell the rights more
0 stars


Nuvo iisued Q2 on July 30 in 2014. Q2 /14 report for comparison..   uvo Research loses $2.3-million in Q2 2014-07-30 17:19 ET - News Release   An anonymous director reports NUVO more
0 stars

RE:Income Calculations

Amen to that brother!  rate and reply
0 stars


Horizon reports next Monday.Nuvo?  rate and reply
5 stars

Income Calculations

No matter how many strange formulae you come up with to provide a forecast of NRI earnings for Q2 it will remain the case that 99% of committed long term investors will continue to be losers until: 1) more
0 stars

RE:RE:Worst Case Scenario for Q2

That is correct. Its included in $2.5 million for R&D. For the same quarter last year, it was just under  $2 million. WF10 began in March of 2014. This year, it was later. $900,000 in contingencies more
0 stars

TechTarget NRI ACCUMULATE @5.39

Possible negativity to remain but the stock is short term oversold.  Contrarian TA position. Fundamentals look very good, profitable, EPS increasing. WATCH to accumulate. Good value.  rate and reply
0 stars

RE:Worst Case Scenario for Q2

Not sure you covered off some portion of $5M cost of phase II WF10 costs (perhaps part of your R&D)?  rate and reply